Lemonaid

The business model centers on a transparent, fee-for-service structure, eliminating reliance on insurance for its core services. Revenue is generated through flat fees for one-time virtual consultations and recurring monthly subscriptions for ongoing care management, such as for mental health or weight loss programs. The platform serves individuals over 18 in all 50 U.S. states, targeting consumers who seek convenient and discreet alternatives to in-person medical appointments. After a patient completes an online assessment, a team of U.S.-licensed doctors and nurse practitioners reviews the case, provides a diagnosis, and, if appropriate, issues a prescription. The company's integrated mail-order pharmacy then ships medications directly to the patient's home, typically within a few days.

Lemonaid Health's service portfolio is extensive, covering a wide range of common medical conditions. These include men's and women's health issues like erectile dysfunction and birth control, mental health services for anxiety and depression, primary care, skin conditions, and various lab testing services. A significant milestone occurred in late 2021 when 23andMe acquired Lemonaid Health for $400 million, a deal comprising 25% cash and 75% stock. This strategic acquisition was aimed at integrating Lemonaid's telemedicine and pharmacy capabilities with 23andMe's genetic data, with a shared vision of creating a personalized primary care experience where treatments are informed by genetic insights.